ʻO NovoNorm he mea hōʻeuʻeu pancreatic. Ma ka maʻi mellitus, hoʻohana ʻia kēia lāʻau lapaʻau inā ʻaʻole lawa ka insulin i ke koko o ka mea maʻi, a pono e hoʻoikaika ʻia kāna hana ʻana. ʻO kahi hiʻohiʻona o ka lāʻau lapaʻau ka hopena wikiwiki a me ka manawa pōkole, hiki iā ʻoe ke hoʻohana iā ia e hoʻoponopono i ka pae o ka glycemia postprandial, ʻo ia hoʻi, e hōʻemi ana i ka glucose mai ka meaʻai.
Inā hoʻohana ʻole pololei, hiki i ka NovoNorm ke kumu hypoglycemia, no laila he mea nui loa e koho i kahi lawa kūpono. Ua kuhikuhi ʻia ke ʻano lāʻau mua e ke kauka, kākau nō hoʻi ia i kahi papa kuhikuhi, e like me ia i hiki ai iā ʻoe ke kūʻai i ka lāʻau. I ka wā e hiki mai ana, hiki i ka maʻi maʻi maʻi kūʻokoʻa ke hoʻoponopono pilikino i ka hoʻohana ʻana, me ka hoʻohana ʻana i nā loiloi mai nā kuhikuhi no ka hoʻohana.
Ka hoʻonohonoho ʻana a me ke ʻano o ka hoʻokuʻu ʻana
Hoʻokuʻu ʻia ka NovoNorm e ka hopohopo NovoNordisk, kahi mea hana kaulana Danish i nā lāʻau lapaʻau a me nā huahana e pili ana no ka maʻi maʻi. Hana ʻia nā papa ma Kelemānia a me Denemaka. ʻO ka mea ikaika o ka lāʻau lapaʻau, repaglinide, he kumupaʻa o nā waikawa amino a lilo i nā secretogens hana pōkole. No Alemania mai (mea hana Beringer Ingelheim).
ʻO ka maʻi maʻi a me nā hoʻohaʻahaʻa manaʻo e hana ia i ka wā ma mua
- Ka hana maʻamau o ke kō -95%
- Hoʻokuʻuina o ka pua thrombosis - 70%
- Hoʻopau i kahi puʻuwai ikaika -90%
- Hoʻopau i ke kiʻekiʻe o ke koko - 92%
- ʻO ka hoʻonuiʻana i ka ikehu i ka wā, hoʻomaikaʻi i ka hiamoe i ka pō -97%
ʻO kekahi papa NovoNorm e loaʻa ka 0.5, 1 a i ʻole 2 mg o ka mea ikaika. Hoʻohui ia, ʻoi, povidone, pāpaʻi polyacrylate, pluronic, glycerin, calcium hydrogen phosphate, a me nā ʻomo. He mau mea kōkua lākou, ʻo ia hoʻi, ʻaʻohe hopena therapeutic.
Pehea e hoʻoholo ai i ka lāʻau lapaʻau mua:
- No ka pale ʻana i nā fakes, ua hōʻailona ʻia kēlā me kēia papa me ka hōʻailona o NovoNordisk - kahi bipi kaulike kahiko o ʻAigupita.
- Hoʻokomo ʻia ka lāʻau lapaʻau i nā blil foil, kēlā me kēia papa he 15 papa.
- Hoʻopiliʻia ka pister me ka perforation, e ʻae ai iā ʻoe e hoʻokaʻawale i kēlā me kēia lā me ka ʻole o ka hoʻohana ʻana i nā ʻihi.
- ʻOkoʻa ke waihoʻoluʻu o nā papa o nā ʻokoʻa like ʻole: 0.5 mg keʻokeʻo, 1 mg melemele, 2 mg pinkish.
ʻO ke kumu o kahi kāʻei e pili ana i nā papa 30 he nui iʻoi aku ma mua o 230 rubles. Hiki ke mālama ʻia ka lāʻau lapaʻau no 5 mau makahiki ma kahi mahana o 15-30 ° C.
ʻO ke kuʻina o ka hana o NovoNorma
ʻO Repaglinide kahi ʻāpana o nā hui lāʻau i kapa ʻia ʻo meglitinides. E hiki iā ʻoe ke hoʻomaopopo iā lākou ma ka hope o ka-glinid ma ka inoa. ʻO lākou nā kumuhana o nā waikina amino, i ka repaglinide - carbamoyl-methyl-benzoic. Hiki i ka waiwai ke hiki i kahi paina kūikawā o nā homa pākela e kū pono ana i nā membrane o nā cell beta pancreatic. Ma lalo o ka mana o ka repaglinide, e pāpā ʻia kēia mau ala, e alakaʻi ana i ke komo ʻana o ka calcium i nā puna a hoʻonui i ka synthesis o ka insulin.
ʻO ka hoʻokuʻuʻana i ka insulin i hoʻonāukiuki ʻia e NovoNorm e hoʻomaka i 10 mau minuke ma hope o ka papa i hoʻokomo i ka pā ʻo ka digestive. ʻIke ʻia ka pae kiʻekiʻe loa i ke koko ma hope o 50 mau minuke. Inā lawe ʻoe i ka lāʻau lapaʻau ma 15 mau minuke ma mua o ka ʻaina, ka ulu ʻana o ke kipi o ke koko a hoʻoulu i ka synthesis o ka insulin coincide i ka manawa, ʻo ia ke ʻano o ka glucose i haʻalele a haʻalele i nā moku.
ʻAʻole like me ka derivatives sulfonylurea kaulana (Maninil, Amaril, Glibenclamide, etc.), ka hana a NovoNorm hilinaʻi i ka glycemia. Me ke kō maʻamau, ʻoi aku ka nui o ka hana ma mua o ka nui o ke kō. Ma hope o ka noi ʻana iā Repaglinide, hoʻi hou ka pae insulin i ka maʻamau ma hope o 3 mau hola. Wahi a nā kauka, ʻo kēia hiʻohiʻona e hōʻemi i ka nui a me ka paʻakikī o ka hypoglycemia i kahi hihia o ka overdose. Kuhi ʻia kēlā luhi ʻana i ka insulin e manaʻo ʻia ana he sparing, e pale ana i ka piʻi wikiwiki ʻana o nā hua beta, a laila hoʻi i ka holomua o ka maʻi diabetes.
Nā hiʻohiʻona o ka haʻaleleʻana mai ke kino
Hiki ke hele koke ʻo Repaglinide i ka hoʻoili manu ʻana, ma muli o ka hoʻomaka mua o kāna hana. Bioavailability a me ka paʻa loa o ka waiwai i loko o ke koko ʻokoʻa nui (a hiki i 60%) i nā maʻi maʻi like, no laila, pono ke koho pākahi ʻia ka dosage no kēlā me kēia maʻi.
Hoʻopili ʻia ka Repaglinide e ka ʻāʻī, ma hope o hoʻokahi hola ka hoʻemi ʻia kona ʻona e ka hapalua. ʻO ka hiʻohiʻona nui o ka pharmacokinetics o kahi meaʻokoʻa ka hoʻopili mai ke kino i ka nui ma o ka digestive tract. Wahi a nā ʻōlelo kuhikuhi, e puka mai ana ʻo 92% o ka repaglinide me nā feces, 2% o lākou ma ke ʻano o ka mea ikaika, ʻo ke koena 90% ma ke ʻano o nā metabolites. Hoʻokomo ʻia nā pūpū i kahi 8%, e hiki ai iā NovoNorm ke hoʻohana i loko o ka maʻi maʻi me nā maʻi puʻuwai koʻikoʻi. Ma hope o 5 mau hola, ʻaʻole ʻike hou ka repaglinide i ke koko.
ʻO ka mea nāna e kuhikuhi i ka lāʻau
Ua kuhikuhi ʻia ʻo NovoNorm no nā maʻi maʻi type 2 i nā pilikia aʻe:
- E hui pū me ka metformin i hope koke o ka hoʻomaka ʻana o ka maʻi, inā ua kiʻekiʻe loa ka hemoglobin glycated ma mua o 9%, e hōʻike ana i ka ʻike ʻole ʻia o ka maʻi mellitus o ka maʻi mellitus a i ʻole ka wikiwiki wikiwiki.
- ʻO kahi mea hou e kū pono ai i ka olalona, inā he mau contraindicated ma muli o ka maʻi keiki, nā hopena alerine.
- Ma ke ʻāpana o nā lāʻau paʻakikī, nā maʻi me ka maʻi maʻi lōʻihi, inā e loaʻa iā lākou ka hemahema o ka insulin a i ʻole ka paukū 1 o kāna hana e hoʻopilikia ʻia (piʻi ka honu i hāʻule a ʻaʻole hāʻule i ka wā lōʻihi ma hope o ka ʻai).
- ʻO nā maʻi maʻi e hiki ʻole ai ke hoʻonohonoho i kā lākou ʻai. Hiki ke loli ka hopena o NovoNorm ma muli o ka nui o nā waihona lae i ka meaʻai.
Ke aʻo nei no ka hoʻohana ʻana i ka lawe ʻana iā NovoNorm me metformin a me glitazones. Wahi a nā loiloi, hele maikaʻi ka lāʻau lapaʻau me nā pūʻulu āpau o nā māka hypoglycemic, e komo pū me ka insulin. ʻO ka mea wale nō ka hoʻomākaukau no ka sulfonylurea. ʻO ka hui pū ʻana me NovoNorm e ʻae ʻia, akā ʻaʻole i ʻōlelo ʻia, no ka mea e hiki ai i ka hypoglycemia koʻikoʻi a hoʻopilikia i ka mokuʻā o nā cell beta.
Nā Hoʻohui
ʻO ka papa inoa o nā contraindications no ka hoʻohana ʻana o NovoNorm i ka maʻi diabetes mellitus:
Kanohau | Kumu no ka pāpā |
ʻO nā maʻi o nā hua o ka pōpoki. | Hiki i nā maʻi maʻi maʻi maʻi hōʻeha i ka pīhoihoi anaphylactic. |
1 ʻano maʻi o ka maʻi diabetes. | Hōʻike ʻia kēia ʻano maʻi maʻi e ka lawehala piha o nā beta beta, kahi e kāpae nei i ka hana o kāna insulin. |
Ketoacidosis a me nā hoʻopiʻi hopena hopena - precoma a me kahi coma. | Hoʻopilikia paha ka hoʻopili ʻana a me ka pau ʻana o ka repaglinide, no laila, hoʻoliʻi iki ʻia nā mea maʻi i ka insulin therapy. Hōʻike nā hōʻike ʻana ma hope o ke kōkua ʻana o kahi kūlana koʻikoʻi, hoʻi ka hapa nui o nā mea maʻi i NovoNorm. |
ʻO nā maʻi koʻikoʻi, nā hana hōʻemi, nā hōʻeha hoʻoweliweli. | |
ʻO ka maʻi ʻana o ka maʻi hepatitis B, ʻoi aku ka liʻiliʻi ma lalo o 18 a ʻoi aku he 75 mau makahiki. | Pāpā ʻia ka hoʻohana ʻia ma muli o ka nele o nā haʻawina e hōʻoia ana i ka palekana o NovoNorm i kēia mau hui o nā maʻi maʻi. |
ʻO ka pīpī hōʻeha momona. | Hoʻokomo ka ate i ka pānaʻi o ka repaglinide, me ka paʻa ʻole, ka piʻiʻana o kahi mea i loko o ke koko. |
ʻO ka lawe ʻana i nā gemfibrozil e hoʻoponopono i nā lipid koko. | Hoʻonui ka mea nui i ka hana a Novo Norm, hiki ke alakaʻi i ka hypoglycemia. Hoʻonui ʻia ke ʻano o ka repaglinide e 2.4 mau manawa, ʻo ka manawa maʻamau ma ka manawa hola e hoʻonui ʻia e 3 mau hola. |
Koho koho
ʻO NovoNorm inu i 15 mau minuke ma mua o ka hoʻopauʻana i nā meaʻai o nā kalama. Hōʻike ka ʻōlelo aʻo i ka hāʻawi ʻana iā ia i nā papa he 2-4 i kēlā me kēia lā i nā mahele like ʻole.
Hoʻoholo ʻia ke koho ana me ka nānā pinepine ʻana o glycemia. Nā Kūlana koho:
- ʻO ka ʻōmai hoʻokahi hoʻomaka he 0.5 mg.
- Inā ʻaʻole i hoʻokō ka uku no ka maʻi diabetes, e hoʻonui ʻia ma hope o 1 hebedoma a 1 mg.
- Ma ka hoʻoulu kūleʻa ʻana i ka huina ma ka 0.5 mg, hiki ke lawe ʻia a hiki i 4 mg ma 1 pāʻai. ʻO ka palena kiʻekiʻe loa o kēlā me kēia lā he 16 mg. Inā ʻaʻole e hāʻawi i ka mana o ka maʻi maʻi, pono e hoʻoponopono ka mea maʻi i ka meaʻai, a inā ʻaʻole pono kēia hana, huli i nā lāʻau ikaika a i ʻole ka insulin.
Hiki i nā hana i makemake ʻole ʻia
Wahi a nā loiloi o ka maʻi maʻi e lawe nei i ka lāʻau lapaʻau, ʻoiai ka nui o ka hālāwai me ka hoʻēmi ʻole ʻana i loko o ka hilo ma hope o ka lawe ʻana i ka paila. ʻO kona kumu he hopena nui loa ia o ka repaglinide, he nele o nā kaʻe o ka ʻai, nā kūlohelohe o kēlā, ke ʻano a me ka noʻonoʻo. ʻImi ʻia ka hopena o ka hypoglycemia e nā ʻōkuhi no ka pinepine (1-10%). Me ka like ʻole e hiki ai - ka ʻeha a me ka ʻeha i loko o ka ʻōpū o ka ʻōpū.
ʻOi aku ka hopena o nā hopena ʻaoʻao ma lalo o ka 0.1% o nā maʻi. Hiki i ka NovoNorm ke hana i nā mālamalama, constipation, nausea, hāʻawi i ka hoʻonui i ka hoʻouluʻana o nā huina o ka huina.
Nā mea inoa a me nā mea e kū nei iā NovoNorma
He aha nā mea e hiki ai ke hoʻololi i NovoNorm inā ʻaʻole palaka a hema ʻole paha i nā lāʻau lapaʻau.
He hui hui | ʻAna inoa, hana | |
ʻO nā analogue, hoʻopau waiwai - repaglinide | Diagninid mai Akrikhin. | |
ʻO Iglinid mai Pharmasynthesis. | ||
Nā hui analog, meglitinides | Starlix (mea waiwai - nateglinide, mea hana iā NovartisPharma). | |
ʻO nā synt synthesis e hoʻonui i nā lāʻau mai nā hui ʻē aʻe | Sulfonylureas | Diabeton (gliclazide, Servier), Maninil (glibenclamide, Berlin-Chemie), Amaryl (glimepiride, Sanofi), Glurenorm (glycvidone, Beringer Ingelheim) a me kā lākou analogues. |
Nā poʻe kikowaena DPP4 | Xelevia (sitagliptin, Berlin-Chemie), Onglisa (saxagliptin, AstraZeneca), Galvus (vildagliptin, NovartisFarma), etc. |
Ma ka maʻi mellitus, hiki ke hana kūʻokoʻa i ka NovoNorm me nā mea kikoʻī o ke kikowaena, inu lākou i ka lāʻau hou i ka hopena like. Ke hoʻololi nei i kekahi mau papa ʻē aʻe mai ka papa ma luna nei e pono ai ke koho i ka pakanā a hiki ke hana ʻia ma lalo o ka nānā a me ka hāʻawi ʻana i kahi kauka.